Bexitrol F MDPI 50 mcg+100 mcg is a fixed-dose combination dry powder inhaler containing Salmeterol and Fluticasone Propionate, developed for the regular maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). This low-dose corticosteroid combination is especially suitable for patients with mild to moderate persistent asthma who require both long-acting bronchodilation and anti-inflammatory control.

The MDPI (Metered Dose Powder Inhaler) device ensures consistent and accurate delivery of medication directly to the lungs, enhancing therapeutic efficacy while reducing systemic exposure. Bexitrol F MDPI is intended for long-term control and should be used regularly as prescribed. It is not indicated for the relief of sudden or acute asthma symptoms.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Long-acting beta-2 agonist (LABA) + Inhaled corticosteroid (ICS)

Indications

Bexitrol F MDPI 50 mcg+100 mcg is indicated for:

• Maintenance treatment of bronchial asthma in patients inadequately controlled on inhaled corticosteroids alone

• Long-term control of asthma symptoms such as wheezing, shortness of breath, chest tightness, and cough

• Maintenance therapy of COPD where combination treatment is appropriate

This strength is commonly prescribed for patients requiring step-up therapy from low-dose inhaled corticosteroids.

Pharmacology

Salmeterol is a selective long-acting beta-2 adrenergic receptor agonist. It produces prolonged relaxation of bronchial smooth muscles, resulting in sustained bronchodilation for up to 12 hours. This helps prevent bronchospasm and improves airflow during both daytime and nighttime.

Fluticasone Propionate is a potent inhaled corticosteroid with strong anti-inflammatory activity. It works by inhibiting the release of inflammatory mediators, reducing airway swelling, mucus secretion, and hyper-responsiveness. Regular use helps prevent asthma exacerbations and improves overall lung function.

The combined action of Salmeterol and Fluticasone Propionate provides superior symptom control compared to either agent alone.

Dosage and Administration

Bexitrol F MDPI is for inhalation use only.

• The usual recommended dose is one inhalation twice daily or as directed by a physician

• The inhaler should be used regularly at the same times each day

• Patients should rinse their mouth with water after inhalation and spit it out to reduce the risk of oral candidiasis

Proper inhaler technique is essential for optimal therapeutic benefit.

Contraindications

Bexitrol F MDPI is contraindicated in:

• Patients with known hypersensitivity to Salmeterol, Fluticasone Propionate, or any component of the formulation

• Acute asthma attacks or episodes of severe bronchospasm requiring rapid-acting bronchodilators

Side Effects

Commonly reported side effects include:

• Throat irritation or hoarseness

• Headache

• Cough

• Oral fungal infections

• Tremor or palpitations (rare)

Most side effects are mild and reversible with correct usage.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not suitable for immediate relief of acute asthma symptoms

• Use with caution in patients with cardiovascular disorders, diabetes mellitus, or thyroid disease

• Do not discontinue therapy abruptly without medical advice

• Long-term use requires periodic medical monitoring

Pregnancy and Lactation

Bexitrol F MDPI should be used during pregnancy and lactation only if clearly needed and prescribed by a healthcare professional after evaluating potential risks and benefits.

Storage Conditions

Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children.

Conclusion

Bexitrol F MDPI 50 mcg+100 mcg is an effective and well-tolerated maintenance inhaler for asthma and COPD management. By combining sustained bronchodilation with anti-inflammatory protection, it helps maintain long-term symptom control, reduces exacerbations, and supports improved respiratory health.